Recently our Immunology Director Piotr Stępniak took part in the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting in Washington, which was a great opportunity to meet with top clinitians and researchers working on advancing of immuno-oncology field. This multidisciplinary educational environment was focused on improving outcomes for current and future cancer patients by incorporating new biomarkers of response, treatment modalities and combination strategies.
The event gathered a SITC record breaking audience of nearly five thousand people. During three days of presentations, exhibition, poster viewing and networking a lot of fresh information was discussed, including first-in-human data of newly targeted checkpoint inhibitors and cancer vaccines. A lot of attention was also drawn to explanatory analyses of clinical trials, especially some failed ones. We recommend SITC’s highlights from Day 1, Day 2 and Day 3.
Keynote by Dr. Philip D. Greenberg, 2018 Recipient of the Richard V. Smalley, MD, Memorial Award and Lectureship